

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application:

Listing of Claims:

1. (Currently amended) An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 1, wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody.
2. (Currently amended) An antibody variable region comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody.
3. (Original) The antibody variable region of claim 2 further comprising the amino acid sequence set forth in SEQ ID NO: 1.
4. (Original) The antibody variable region of claim 3, wherein the amino acid sequences are linked by a disulfide bond.
5. (Original) The antibody variable region of claim 3, wherein the amino acid sequences are linked by a peptide bond.
6. (Currently amended) An antibody variable region comprising an amino acid sequence selected from the group consisting of amino acids 1-23 of SEQ ID NO: 1, amino acids 1-25 of SEQ ID NO: 2, and amino acids 67-98 of SEQ ID NO: 2, wherein the antibody variable region (i) is capable of binding to human GD2 and, (ii) when administered to a human patient, is less immunogenic than a variable region of a mouse anti-GD2 antibody-specifically binds to GD2.

7. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-23 of SEQ ID NO: 1.
8. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 1-25 of SEQ ID NO: 2.
9. (Original) The antibody variable region of claim 6, wherein the amino acid sequence includes amino acids 67-98 of SEQ ID NO: 2.
10. (Original) A polypeptide comprising the antibody variable region of claim 6 and an Fc portion comprising at least a CH2 domain.
11. (Original) The polypeptide of claim 10, wherein the Fc portion is derived from IgG1.
12. (Cancelled)
13. (Cancelled)
14. (Original) A method for targeting a cell with GD2 on its surface, the method comprising:
administering the antibody variable region of claim 6.
15. (Original) The method of claim 14, wherein the cell is a tumor cell.
16. (Original) A fusion protein comprising the antibody variable region of claim 6 and a non-immunoglobulin moiety.
17. (Original) The fusion protein of claim 16, wherein the non-immunoglobulin moiety is a cytokine.

18. (Original) The fusion protein of claim 17, wherein the cytokine is selected from the group consisting of an interleukin, a hematopoietic factor, a lymphokine, an interferon, and a chemokine.

19. (Currently amended) The fusion protein of claim 18, wherein the cytokine is an interleukin is selected from the group consisting of interleukin-2 (IL-2) and interleukin-12 (IL-12).

20. (Currently amended) The fusion protein of claim 18, wherein the cytokine is a ~~hematopoietic factor is~~ granulocyte-macrophage colony stimulating factor (GM-CSF).

21. (Currently amended) The fusion protein of claim 18, wherein the cytokine is ~~lymphokine is~~ a lymphotoxin.

22. (Currently amended) The fusion protein of claim 18, wherein the cytokine is an ~~interferon is~~ selected from the group consisting of interferon- α , interferon- β , and interferon- γ .

23. (Original) The fusion protein of claim 16 further comprising a second non-immunoglobulin moiety.

24. (Original) The fusion protein of claim 23, wherein the fusion protein comprises IL-2 and IL-12.

25. (Cancelled)

26. (Cancelled)

27. (New) A method for targeting a cell with GD2 on its surface, the method comprising administering the antibody variable region of claim 1.

28. (New) The method of claim 27, wherein the cell is a tumor cell.

29. (New) The method of claim 27, wherein the antibody variable region is administered to a human patient.

30. (New) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 1.

31. (New) A method for targeting a cell with GD2 on its surface, the method comprising administering the antibody variable region of claim 2.

32. (New) The method of claim 31, wherein the cell is a tumor cell.

33. (New) The method of claim 31, wherein the antibody variable region is administered to a human patient.

34. (New) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 2.

35. (New) A method for targeting a cell with GD2 on its surface, the method comprising administering the polypeptide of claim 10.

36. (New) The method of claim 35, wherein the cell is a tumor cell.

37. (New) The method of claim 35, wherein the polypeptide is administered to a human patient.

38. (New) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the polypeptide of claim 10.

39. (New) A method for targeting a cell with GD2 on its surface, the method comprising administering the fusion protein of claim 16.

40. (New) The method of claim 39, wherein the cell is a tumor cell.

41. (New) The method of claim 39, wherein the fusion protein is administered to a human patient.
42. (New) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the fusion protein of claim 16.
43. (New) The method of claim 14, wherein the antibody variable region is administered to a human patient.
44. (New) A method of treating a human cancer patient, wherein the method comprises administering to the patient an effective amount of the antibody variable region of claim 6.